<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0123-9392</journal-id>
<journal-title><![CDATA[Infectio]]></journal-title>
<abbrev-journal-title><![CDATA[Infect.]]></abbrev-journal-title>
<issn>0123-9392</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Infectología.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0123-93922019000400382</article-id>
<article-id pub-id-type="doi">10.22354/in.v23i4.807</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[New antibiotics against bacterial resistance]]></article-title>
<article-title xml:lang="es"><![CDATA[Nuevos antibióticos contra la resistencia bacteriana]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cárdenas]]></surname>
<given-names><![CDATA[Lorena Liseth]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Merchán]]></surname>
<given-names><![CDATA[Maritza Angarita]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[Diana Paola]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Boyacá Facultad Ciencias de la Salud Grupo de Investigación de Bacteriología y Laboratorio Clínico]]></institution>
<addr-line><![CDATA[Boyacá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<volume>23</volume>
<numero>4</numero>
<fpage>382</fpage>
<lpage>387</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0123-93922019000400382&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0123-93922019000400382&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0123-93922019000400382&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract The evolution of bacterial resistance is generating a serious public health problem due to the indiscriminate use of antibiotics, the application of non-optimal doses, the irregularity in the taking of medicines sent by the health professional, factors that have affected the increase in the rate of antimicrobial resistance; It is important to generate strategies that contribute to diminishing it, including the rational use of antibiotics and the constant research of new therapeutic alternatives such as teixobactin, which is a product of the Gram negative bacterium called Eleftheria terrae, related to the genus Aquabacterium, is a microorganism that presents extremophile conditions, for which, a multichannel system of semipermeable membranes called Ichip was developed for its isolation. Eravacycline is a new fully synthetic bacteriostatic antibiotic of the tetracycline family, is a potent inhibitor based on the mechanism of the bacterial ribosome and exerts potent activity against a broad spectrum of susceptible and multiresistant bacteria.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La evolución de la resistencia bacteriana ha generado un serio problema de salud pública debido al uso indiscriminado antibioticos, la aplicación de dosis no óptimas, la irregularidad en la toma de medicinas prescritas por el profesional de la salud han llevado a un aumento en la tasa de resistencia antimicrobiana; por ello es importante generar estrategias que contribuyan a disminuirla incluyendo el uso racional de anitibioticos y la búsqueda constante de nuevos antibioticos. La teixobactina es un producto de bacterias gram negativas llamadas Eleftheria terrae, relacionadas con el género Aquabacterium, el cual es un microorganismo que presenta condiciones extremofilas. Para el aislamiento de este nuevo compuesto se utilizó un sistema multicanal de membranas semipepermeables llamadas Ichip. Eravaciclina es un nuevo antibiotico síntetico bacteriostatico de la familia de las tetraciclinas y es un potente inhibidor de la maquinaria ribosomal bacteriana, con una potente actividad contra un amplio espectro de bacterias multirresistentes.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[teixobactin]]></kwd>
<kwd lng="en"><![CDATA[eravacycline]]></kwd>
<kwd lng="en"><![CDATA[tetracycline]]></kwd>
<kwd lng="en"><![CDATA[bacterial resistance]]></kwd>
<kwd lng="en"><![CDATA[lipid II]]></kwd>
<kwd lng="en"><![CDATA[Eleftheria Terrae]]></kwd>
<kwd lng="en"><![CDATA[Ichip]]></kwd>
<kwd lng="es"><![CDATA[teixobactina]]></kwd>
<kwd lng="es"><![CDATA[eravacyclina]]></kwd>
<kwd lng="es"><![CDATA[tetracyclina]]></kwd>
<kwd lng="es"><![CDATA[resistencia bacteriana]]></kwd>
<kwd lng="es"><![CDATA[lipid II]]></kwd>
<kwd lng="es"><![CDATA[Eleftheria Terrae]]></kwd>
<kwd lng="es"><![CDATA[Ichip]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lam]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Discovering antibiotics from the global microbiome]]></article-title>
<source><![CDATA[Nat Microbiol]]></source>
<year>2018</year>
<volume>3</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>392-3</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cars]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Securing access to effective antibiotics for current and future generations. Whose responsibility?]]></article-title>
<source><![CDATA[Ups J Med Sci]]></source>
<year>2014</year>
<volume>119</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>209-14</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Strategia]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Anexa]]></surname>
<given-names><![CDATA[S-]]></given-names>
</name>
<name>
<surname><![CDATA[Rom]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Proiect]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Eir]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Dezvolt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Resistencia bacteriana: un problema de salud pública mundial de difícil solución]]></article-title>
<source><![CDATA[Mem. Inst. Investig. Cienc. Salud]]></source>
<year>2016</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>45-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nathan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cars]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibiotic Resistance - Problems, Progress, and Prospects]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2014</year>
<volume>371</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1761-3</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Reynolds]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Simons]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Resistencia emergente a los antibióticos: una amenaza global y un problema crítico en el cuidado de la salud]]></article-title>
<source><![CDATA[Rev Peru Med Exp Salud Publica]]></source>
<year>2015</year>
<volume>32</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>139-45</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cruz Cruz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibióticos vs . resistencia bacteriana Antibiotics vs . bacterial resistance]]></article-title>
<source><![CDATA[Rev Electrónica Dr Zoilo E Mar Vidaurreta]]></source>
<year>2015</year>
<page-range>40</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gautman]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Científicos descubren un nuevo y potente antibiótico]]></article-title>
<source><![CDATA[Wall Str J Am]]></source>
<year>2015</year>
<page-range>1-2</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giltrap]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Dowman]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Nagalingam]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ochoa]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Linington]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Britton]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Total Synthesis of Teixobactin]]></article-title>
<source><![CDATA[Org Lett]]></source>
<year>2016</year>
<volume>18</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2788-91</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piddock]]></surname>
<given-names><![CDATA[LJV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Teixobactin, the first of a new class of antibiotics discovered by ichip technology?]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2015</year>
<volume>70</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2679-80</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mandalapu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ji]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chemistry and Biology of Teixobactin]]></article-title>
<source><![CDATA[Chem - A Eur J]]></source>
<year>2018</year>
<volume>24</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>5406-22</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buckland]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[New antibiotic candidates that offer potential]]></source>
<year>2017</year>
<month>;(</month>
<day>Ja</day>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arias]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A New Antibiotic and the Evolution of Resistance]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>372</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1168-70</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[TEIXOBACTINA : UNA NUEVA FAMILIA DE ANTIBIÓTICOS]]></article-title>
<source><![CDATA[Northeast Univ]]></source>
<year>2015</year>
<volume>1</volume>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Von Nussbaum]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Süssmuth]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multiple attack on bacteria by the new antibiotic teixobactin]]></article-title>
<source><![CDATA[Angew Chemie - Int Ed]]></source>
<year>2015</year>
<volume>54</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>6684-6</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sherpa]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Reese]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Aliabadi]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Application of iChip to grow &#8220;uncultivable&#8221; microorganisms and its impact on antibiotic discovery]]></article-title>
<source><![CDATA[J Pharm Pharm Sci]]></source>
<year>2015</year>
<volume>18</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>303-15</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kali]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Teixobactin: A novel antibiotic in treatment of gram positive bacterial infections]]></article-title>
<source><![CDATA[J Clin Diagnostic Res]]></source>
<year>2015</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abdel Monaim]]></surname>
<given-names><![CDATA[SAH]]></given-names>
</name>
<name>
<surname><![CDATA[Jad]]></surname>
<given-names><![CDATA[YE]]></given-names>
</name>
<name>
<surname><![CDATA[Ramchuran]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[El-Faham]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Govender]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kruger]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lysine Scanning of Arg 10 -Teixobactin: Deciphering the Role of Hydrophobic and Hydrophilic Residues]]></article-title>
<source><![CDATA[ACS Omega]]></source>
<year>2016</year>
<volume>1</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1262-5</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Viñuales]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La teixobactina y el iChip : nuevas armas contra la Resistencia antibiótica]]></article-title>
<source><![CDATA[MoleQla Rev Ciencias la Univ Pablo Olavide]]></source>
<year>2016</year>
<volume>23</volume>
<page-range>1-3</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Monaim]]></surname>
<given-names><![CDATA[SAHA]]></given-names>
</name>
<name>
<surname><![CDATA[Noki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ramchuran]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[El-Faham]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Albericio]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Torre]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Investigation of the N-Terminus Amino Function of Arg10-Teixobactin]]></article-title>
<source><![CDATA[Molecules]]></source>
<year>2017</year>
<volume>22</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kirby]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New antibiotic development hailed as game changing]]></article-title>
<source><![CDATA[Lancet Infect Dis]]></source>
<year>2015</year>
<volume>15</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>271-2</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parmar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Iyer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Prior]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Lloyd]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Leng Goh]]></surname>
<given-names><![CDATA[ET]]></given-names>
</name>
<name>
<surname><![CDATA[Vincent]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Teixobactin analogues reveal enduracididine to be non-essential for highly potent antibacterial activity and lipid II binding]]></article-title>
<source><![CDATA[Chem Sci]]></source>
<year>2017</year>
<volume>8</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>8183-92</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[OJ]]></given-names>
</name>
<name>
<surname><![CDATA[Debashree]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Raleng]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Teixobactin: an Antibiotic With Undetectable Resistance]]></article-title>
<source><![CDATA[J Evol Res Med Pharmacol]]></source>
<year>2015</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>21-2</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reddy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dhara]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gunjal]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Handore]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COMMUNICATION A SolutionPhase Synthesis of Macrocyclic Core of Teixobactin]]></article-title>
<source><![CDATA[European J Org Chem]]></source>
<year>2016</year>
<volume>10</volume>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abdel Monaim]]></surname>
<given-names><![CDATA[SAH]]></given-names>
</name>
<name>
<surname><![CDATA[Ramchuran]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[El-Faham]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Albericio]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[De La Torre]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Converting Teixobactin into a Cationic Antimicrobial Peptide (AMP)]]></article-title>
<source><![CDATA[J Med Chem]]></source>
<year>2017</year>
<volume>60</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>7476-82</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ling]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Schneider]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Peoples]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Spoering]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Engels]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Conlon]]></surname>
<given-names><![CDATA[BP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A new antibiotic kills pathogens without detectable resistance]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2015</year>
<volume>517</volume>
<numero>7535</numero>
<issue>7535</issue>
<page-range>455-9</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
<name>
<surname><![CDATA[Nowick]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Elucidation of the Teixobactin Pharmacophore]]></article-title>
<source><![CDATA[ACS Chem Biol]]></source>
<year>2016</year>
<volume>11</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1823-6</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lungu]]></surname>
<given-names><![CDATA[CN]]></given-names>
</name>
<name>
<surname><![CDATA[Diudea]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Binding Site and Potency Prediction of Teixobactin and other Lipid II Ligands by Statistical Base Scoring of Conformational Space Maps]]></article-title>
<source><![CDATA[Curr Comput Aided Drug Des]]></source>
<year>2018</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>29-34</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Chan-Park]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Mu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Binding Modes of Teixobactin to Lipid II: Molecular Dynamics Study]]></article-title>
<source><![CDATA[Sci Rep]]></source>
<year>2017</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-12</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[PO]]></given-names>
</name>
<name>
<surname><![CDATA[Heil]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Covert]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Cluck]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment strategies for persistent methicillin-resistant Staphylococcus aureus bacteraemia]]></article-title>
<source><![CDATA[J Clin Pharm Ther]]></source>
<year>2018</year>
<volume>43</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>614-25</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grossman]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
<name>
<surname><![CDATA[Starosta]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Fyfe]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Brien]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Rothstein]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Mikolajka]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2012</year>
<volume>56</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>2559-64</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xiao]]></surname>
<given-names><![CDATA[XY]]></given-names>
</name>
<name>
<surname><![CDATA[Hunt]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Clark]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Dunwoody]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Fyfe]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: A potent, broad spectrum antibacterial agent]]></article-title>
<source><![CDATA[J Med Chem]]></source>
<year>2012</year>
<volume>55</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>597-605</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Solomkin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Slepavicius]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Marsh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tsai]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessing the efficacy and safety of Eravacycline vs Ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE 1) trial a randomized clinical trial]]></article-title>
<source><![CDATA[JAMA Surg]]></source>
<year>2017</year>
<volume>152</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>224-32</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clark]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Hunt]]></surname>
<given-names><![CDATA[DK]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Achorn]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Deng]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy]]></article-title>
<source><![CDATA[J Med Chem]]></source>
<year>2012</year>
<volume>55</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>606-22</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Bush]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In vitro susceptibility of &#946;-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline]]></article-title>
<source><![CDATA[J Antibiot (Tokyo)]]></source>
<year>2016</year>
<volume>69</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>600-4</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ronn]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Hogan]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[WY]]></given-names>
</name>
<name>
<surname><![CDATA[Niu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Katz]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Process R&amp;D of eravacycline: The first fully synthetic fluorocycline in clinical development]]></article-title>
<source><![CDATA[Org Process Res Dev]]></source>
<year>2013</year>
<volume>17</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>838-45</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Starosta]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Arenz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sohmen]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Dönhöfer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tetracycline antibiotics and resistance mechanisms]]></article-title>
<source><![CDATA[Biol Chem]]></source>
<year>2014</year>
<volume>395</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>559-75</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thabit]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Monogue]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Nicolau]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eravacycline pharmacokinetics and challenges in defining humanized exposure in vivo]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2016</year>
<volume>60</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>5072-5</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Snydman]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[McDermott]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobus N]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Kerstein]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Grossman]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
<name>
<surname><![CDATA[Sutcliffe]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of the in vitro activity of eravacycline against a broad spectrum of recent clinical anaerobic isolates]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2018</year>
<volume>62</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>617-36</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jenner]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Starosta]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Terry]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Mikolajka]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Filonava]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Yusupov]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Structural basis for potent inhibitory activity of the antibiotic tigecycline during protein synthesis]]></article-title>
<source><![CDATA[Proc Natl Acad Sci]]></source>
<year>2013</year>
<volume>110</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>3812-6</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Atkinson]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Thakor]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Allas]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Yan Chan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanism of tetracycline resistance by ribosomal protection protein Tet(O)]]></article-title>
<source><![CDATA[Nat Commun]]></source>
<year>2013</year>
<page-range>4</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ribosome-targeting antibiotics and mechanisms of bacterial resistance]]></article-title>
<source><![CDATA[Nat Rev Microbiol]]></source>
<year>2014</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>35-48</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Solomkin]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Ramesh]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Cesnauskas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Novikovs]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Stefanova]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sutcliffe]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2014</year>
<volume>58</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1847-54</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Monogue]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Thabit]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Hamada]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Nicolau]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibacterial efficacy of eravacycline In Vivo against gram-positive and gram-negative organisms]]></article-title>
<source><![CDATA[Antimicrob Agents Chemother]]></source>
<year>2016</year>
<volume>60</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>5001-5</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thabit]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Monogue]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Newman J]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Nicolau]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysis]]></article-title>
<source><![CDATA[Int J Antimicrob Agents]]></source>
<year>2018</year>
<volume>51</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>727-32</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goldstein]]></surname>
<given-names><![CDATA[EJC]]></given-names>
</name>
<name>
<surname><![CDATA[Citron]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Tyrrell]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In vitro activity of eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides and Parabacteroides species]]></article-title>
<source><![CDATA[Anaerobe]]></source>
<year>2018</year>
<volume>52</volume>
<page-range>122-4</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tran]]></surname>
<given-names><![CDATA[BT]]></given-names>
</name>
<name>
<surname><![CDATA[Tam]]></surname>
<given-names><![CDATA[VH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The complexity of minocycline serum protein binding]]></article-title>
<source><![CDATA[J Antimicrob Chemother]]></source>
<year>2017</year>
<volume>72</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1632-4</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Avery]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Nicolau]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria]]></article-title>
<source><![CDATA[Expert Opinion on Investigational Drugs]]></source>
<year>2018</year>
<volume>Vol. 27</volume>
<page-range>325-38</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Platforms for antibiotic discovery]]></article-title>
<source><![CDATA[Nat Rev Drug Discov]]></source>
<year>2013</year>
<volume>12</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>371-87</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Braff]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Shis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Synthetic biology platform technologies for antimicrobial applications]]></article-title>
<source><![CDATA[Adv Drug Deliv Rev]]></source>
<year>2016</year>
<volume>105</volume>
<page-range>35-43</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Slomovic]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pardee]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Synthetic biology devices for in vitro and in vivo diagnostics]]></article-title>
<source><![CDATA[Proc Natl Acad Sci]]></source>
<year>2015</year>
<volume>112</volume>
<numero>47</numero>
<issue>47</issue>
<page-range>14429-35</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
